SCHEMBL5725399

SCHEMBL5725399

CS(=O)(=O)N(CCCOc1cc(Cl)cc(Cl)c1)CCCc1ccc(C(=O)O)s1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 3/20 0.41
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.36
MCL1 Q07820 5/20 0.35
BCL2 P10415 2/20 0.35
BCL2L1 Q07817 2/20 0.35
BAD Q92934 2/20 0.35
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
PRNP P04156 1/20 0.34
RECQL P46063 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
F2 P00734 1/20 0.33
FOLR1 P15328 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4947427 0.97 MRGPRX4 (0.40) MRGPRX4KDM4EMAPTMCL1BCL2
SCHEMBL5724877 0.96 MRGPRX4 (0.39) MRGPRX4KDM4EMAPTMCL1BCL2
SCHEMBL5726400 0.94 HPGD (0.39) MRGPRX4KDM4EMAPTMCL1BCL2
SCHEMBL13398705 0.92 HPGD (0.42) MRGPRX4KDM4EMAPTMCL1BCL2
SCHEMBL5725422 0.91 HPGD (0.38) MRGPRX4KDM4EMAPTMCL1BCL2
SCHEMBL13399037 0.88 HPGD (0.41) MRGPRX4KDM4EMAPTMCL1BCL2
SCHEMBL14276973 0.88 HDAC3 (0.35) MRGPRX4KDM4EMAPTMCL1ALDH1A1
SCHEMBL5726712 0.88 KDM4E (0.49) MRGPRX4KDM4ETP53TDP1
SCHEMBL13398745 0.87 KDM4E (0.34) MRGPRX4KDM4EMAPTMCL1TP53
SCHEMBL13399155 0.87 KDM4E (0.34) MRGPRX4KDM4EMAPTMCL1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6998423-B2 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. (US) 2006-02-14 US claimed
US-20100105905-A1 EP2 Agonists PFIZER INC. 2010-04-29 US disclosed
US-20100105905-A1 EP2 Agonists PFIZER INC. 2010-04-29 US disclosed
US-7622475-B2 EP2 agonists PFIZER INC (US) 2009-11-24 US disclosed
US-7622475-B2 EP2 agonists PFIZER INC (US) 2009-11-24 US disclosed
US-20080045545-A1 EP2 AGONISTS PFIZER INC. 2008-02-21 US disclosed
US-20080045545-A1 EP2 AGONISTS PFIZER INC. 2008-02-21 US disclosed
EP-0946501-B1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER (US) 2006-05-31 EP disclosed
US-6998423-B2 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. (US) 2006-02-14 US disclosed
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC 2004-09-09 US disclosed
US-6649657-B2 Administering amide to treat osteoporosis PFIZER INC. 2003-11-18 US disclosed
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLEY Q (US) 2003-06-05 US disclosed
US-6344485-B1 Method for treating glaucoma PFIZER INC. 2002-02-05 US disclosed
US-6288120-B1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. 2001-09-11 US disclosed
EP-1000619-A2 Method for treating glaucoma Pfizer Products Inc. (US) 2000-05-17 EP disclosed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 EP disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 MRGPRX4 332/4885KDM4E 3595/4885MAPT 4871/4885
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 MRGPRX4 332/4885KDM4E 3595/4885MAPT 4871/4885
US-20080045545-A1 EP2 AGONISTS PTGER2, PTGER1, PTGIR MRGPRX4 177/4885KDM4E 2123/4885MAPT 4076/4885
US-20100105905-A1 EP2 Agonists PTGER2, PTGER1, PTGIR MRGPRX4 177/4885KDM4E 2123/4885MAPT 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.